Sugi Predict

Sugi Predict / Compounds / SCHEMBL498987

SCHEMBL498987

SCHEMBL498987

CC(C)[C@@H](C=O)NC(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA7 P43166 1/20 0.51
▸ CTSK P43235 11/20 0.50
▸ CYP2D6 P10635 1/20 0.46
▸ CTSS P25774 3/20 0.44
▸ CTSL P07711 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ PREP P48147 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1991719 1.00 CA1 (0.51) CA1CA2CA7CTSKCYP2D6
SCHEMBL1219074 1.00 CA1 (0.51) CA1CA2CA7CTSKCYP2D6
SCHEMBL8893172 0.87 CTSK (0.49) CA1CA2CA7CTSKCYP2D6
SCHEMBL14632348 0.87 CTSK (0.49) CA1CA2CA7CTSKCYP2D6
SCHEMBL30718516 0.87 CTSK (0.49) CA1CA2CA7CTSKCYP2D6
SCHEMBL23989898 0.84 CTSK (0.46) CA1CA2CA7CTSKCYP2D6
SCHEMBL12378789 0.84 CTSK (0.46) CA1CA2CA7CTSKCYP2D6
SCHEMBL3196835 0.84 CTSK (0.46) CA1CA2CA7CTSKCYP2D6
SCHEMBL271515 0.84 CTSK (0.46) CA1CA2CA7CTSKCYP2D6
SCHEMBL2519108 0.84 CTSK (0.46) CA1CA2CA7CTSKCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819693-B1 ANTITHROMBOTIC DIAMIDES LILLY CO ELI (US) 2009-08-26 — — EP claimed
US-20090062271-A1 Antithrombotic Diamides ELI LILLY AND COMPANY (US) 2009-03-05 — — US claimed
US-20070129383-A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-06-07 — — US claimed
EP-1674454-A1 SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2006-06-28 — — EP claimed
US-5977371-A Tandem asymmetric transformation process MERCK & CO., INC. (US) 1999-11-02 — — US claimed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 — — US disclosed
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-06-12 — — US disclosed
EP-4551555-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Vividion Therapeutics, Inc. (US) 2025-05-14 — — EP disclosed
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors VIVIDION THERAPEUTICS, INC. 2025-01-07 — — US disclosed
WO-2024226890-A1 PYRAZOLE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2024-10-31 — — WO disclosed
WO-2024226892-A1 HYDRAZONE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF Verge Analytics, Inc. (US) 2024-10-31 — — WO disclosed
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. 2024-05-02 — — US disclosed
EP-0520427-B1 Cyclopropenone derivatives MITSUBISHI CHEM IND (JP) 1994-12-14 — — EP disclosed
EP-0618221-A2 Heterocyclic inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY (US) 1994-10-05 — — EP disclosed
US-5328909-A Protease inhibitors MITSUBISHI KASEI CORPORATION (JP) 1994-07-12 — — US disclosed
EP-0594540-A1 Antiretroviral acyl compounds CIBA-GEIGY AG (CH) 1994-04-27 — — EP disclosed
EP-0590650-A1 Cyclopropene derivatives with thiol protease inhibiting activity Mitsubishi Chemical Corporation (JP) 1994-04-06 — — EP disclosed
US-5238922-A Anticancer agents MERCK & CO., INC. (US) 1993-08-24 — — US disclosed
EP-0535731-A2 Inhibitors of farnesyl protein transferase MERCK & CO. INC. (US) 1993-04-07 — — EP disclosed
EP-0520427-A1 Cyclopropenone derivatives Mitsubishi Chemical Corporation (JP) 1992-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 CA1 477/4885CA2 309/4885CA7 160/4885
US-20090062271-A1 Antithrombotic Diamides TFPI, SERPINC1, TFPI2 CA1 723/4885CA2 960/4885CA7 946/4885
US-20070129383-A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof ADORA1, ADORA2B, ADORA3 CA1 3471/4885CA2 1359/4885CA7 2361/4885
US-20240140915-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN CA1 4670/4885CA2 4415/4885CA7 4252/4885
US-12187685-B2 Pharmaceutical compositions comprising WRN helicase inhibitors RECQL, BLM, WRN CA1 4670/4885CA2 4415/4885CA7 4252/4885
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN CA1 4670/4885CA2 4415/4885CA7 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.